Table 2.
The characteristics of the patients
| Variabile | Control group | Treatment group | Total | p-value |
|---|---|---|---|---|
| Age; yr, mean ± SD (range) | 50.3 ± 11.3 (28–75) | 51.7 ± 13.8 (18–81) | 51.2 ± 13.0 (18–81) | 0.520 |
| Male; n (%) - | 34 (58.6) | 55 (47.4) | 89 (51.2) | 0.163 |
| BMI; mean ± SD (range) | 31.8 ± 6.2 (22.7–53.0) | 31.0 ± 5.4 (20.7–53.0) | 31.2 ± 5.7 (20.7–53.0) | 0.423 |
| Time from SARS-CoV-2 molecular test positivity; months, mean ± SD (range) | 5.4 ± 2.7 (1–15) | 5.9 ± 3.7 (1–19) | 5.8 ± 3.4 (1–19) | 0.836 |
| Hospitalized patients; n (%) | 9 (15.5) | 22 (19.0) | 31 (17.8) | 0.575 |
|
Hospitalization days; n (%) <10 days >10 days |
1 (11.1) 8 (88.9) | 2 (9.1) 20 (90.9) | 3 (9.7) 28 (90.3) | 0.863 |
| Diabetes; n (%) | 7 (12.1) | 16 (13.8) | 23 (13.2) | 0.752 |
| Ischemic cardiomyopathy; n (%) | 0 (0.0) | 2 (1.7) | 2 (1.2) | 0.315 |
| Heart failure; n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
| Chronic respiratory syndrome; n (%) | 10 (17.2) | 18 (15.5) | 28 (16.1) | 0.770 |
| Psychotropic drug use; n (%) | 2 (3.5) | 3 (2.6) | 5 (2.9) | 0.748 |
| Psychiatric disease; n (%) | 6 (10.3) | 7 (6.0) | 13 (7.5) | 0.308 |
| Neurologic disease; n (%) | 2 (3.5) | 2 (2.6) | 5 (2.9) | 0.748 |
| Autoimmune disease; n (%) | 6 (10.3) | 11 (9.5) | 17 (9.8) | 0.857 |